GSP Crop Science IPO Review: All You Need to Know About the ₹400 Cr Issue

GSP Crop Science is an agrochemical company that makes crop protection products like insecticides, herbicides, fungicides, and plant growth regulators for farmers and agrochemical companies. Its IPO opens from March 16 to March 18, 2026, at a price band of ₹304 to ₹320 per share, and the grey market premium, or GMP, is around zero in recent reports, though GMP is only an unofficial market signal and not a reliable predictor of listing gains.

In this article, we’ll walk through what the company does, how it makes money, where the IPO money will go, what looks strong, what looks risky, how it compares with peers, and what investors should think about before applying.

IPO Overview

• IPO Date: 16 to 18 Mar, 2026
• Total Issue Size: ₹400 crore
• Price Band: ₹304 to ₹320 per share
• Minimum Investment: ₹14,720
• Lot Size: 46 Shares
• Tentative Allotment Date: Mar 20, 2026
• Listing Date: Mar 24, 2026 (Tentative)
• GMP: The GMP for the GSP Crop Science IPO is ₹0, reflecting a 0% gain over the issue price, according to Chittorgarh.com.

Disclaimer: GMP is an unofficial indicator and is subject to market volatility.

How GSP Crop Science Makes Money

• GSP Crop Science makes crop protection chemicals that help farmers protect crops from bugs, weeds, fungus, and plant diseases. It earns money by selling these products as ready-to-use formulations, which are mixed products farmers can spray directly, and as technicals, which are concentrated active chemicals sold to other manufacturers or used in its own products.
• The company works in both B2B and B2C channels. That means it sells to other agrochemical companies in bulk, and it also sells branded products through distributors and retail shops that eventually reach farmers across 20 Indian states.
• Its business starts with research and development, or R&D, which simply means creating new products and improving older ones. After that, it gets approvals, buys raw materials, manufactures products in its five plants, and then moves them through a large network of distributors to the market.
• It also earns from exports, which gives it some balance beyond India. In FY25, overseas revenue was ₹143.93 crore, or 11.18% of total operating revenue, and the company sold in 37 countries, including the US, Brazil, Uruguay, Vietnam, Singapore, the UAE, and Australia.

Objectives of the IPO

The company is raising ₹400 crore via the IPO, including a fresh issue of ₹240 crore and an Offer for Sale of ₹160 crore. The money from the OFS will go to the selling shareholders, namely Vilasben Vrajmohan Shah, Bhavesh Vrajmohan Shah, and Kappa Trust. It plans to use the fresh issue proceeds for the following purposes:

• Repayment of borrowings: The company plans to use ₹170 crore from the fresh issue to repay loans. As of December 30, 2025, total borrowings were ₹478.9 crore, which means a meaningful part of the IPO money is meant to reduce debt and interest burden.
• General corporate purposes: The remaining fresh issue money will be used for general corporate purposes, which usually mean day-to-day business needs, working capital, brand building, and growth spending. This gives the company some flexibility as it expands products, customers, and overseas presence.

Strengths:

• The company has real product depth. It has 524 product registrations, 102 granted patents, and 108 patent applications in process, and patented products brought in ₹143.68 crore in H1 FY26, or 17.10% of product sales, which shows the patents are generating actual revenue, not just sitting on paper.
• It has a strong reach and manufacturing scale. GSP has five plants with an annual capacity of 43,672 MTPA for formulations and 15,120 MTPA for technicals, plus a domestic network of 5,644 distributors in FY25 and business presence across 37 countries.
• ​Profitability has improved sharply. EBITDA margin improved to 12.74% from 6.75% in FY23, and net profit margin rose to 6.26% from 1.46%, which means the company kept ₹6.26 as profit for every ₹100 of sales in FY25 versus only ₹1.46 in FY23.

Risks:

• China's dependence is a real supply risk. In H1 FY26, 42.08% of raw material purchases came from China, costing ₹228.35 crore, so any disruption in supply, freight, or prices could hit production and margins quickly.
• Demand quality needs watching. Sales returns were ₹84.61 crore in H1 FY26, or 8.26% of gross revenue, which might suggest some products may be getting pushed into the channel faster than the real end demand is growing.
• The business is still concentrated in a few products, customers, and regions. Generic products made up 82.90% of H1 FY26 sales, insecticides alone contributed 58.79% of product revenue, the top 10 customers accounted for 22.87% of revenue, and five states contributed 57.37% of revenue, with Gujarat alone at ₹230.23 crore.

For detailed information, visit GSP Crop Science’s official IPO page at INDmoney.

Peer Comparison

Source: RHP, internal calculation

• Revenue scale: GSP’s FY25 operating revenue was ₹1,287.40 crore. That is much smaller than PI Industries at ₹7,977.80 crore and Sumitomo Chemical India at ₹3,148.50 crore, but it is ahead of India Pesticides at ₹828.60 crore and Excel Industries at ₹978.10 crore, so it sits somewhere in the middle of the pack.
• Profitability: GSP’s FY25 EBITDA margin was 12.74%. That means for every ₹100 of sales, the business kept about ₹12.74 as operating profit before interest, tax, and other non-cash costs, which is well below PI Industries at 31.68% but still stronger than weaker peers like Heranba at 7.48%, based on the peer data provided in the IPO material.
• Return ratios and valuation: GSP’s Return on Equity was 18.38% in FY25, which means it earned about ₹18.38 for every ₹100 of shareholder money invested in the business. Its IPO P/E is shown around 15.34 times on the upper band, which is lower than the industry average of 51.81.

IPO Valuation

At the upper price band, the IPO is valued at a P/E of about 9.18 times using annualized H1 FY26 profits. In simple words, a P/E ratio tells you how much investors are paying for every ₹1 of profit, so a P/E of 9.18 means investors are paying ₹9.18 for every ₹1 the company earned.

The post-issue implied market cap is about ₹1,426 crore to ₹1,489 crore. That is not tiny, but it is still much smaller than many listed agrochemical peers, so investors are not buying the sector leader here; they are buying a mid-sized player with patents, improving margins, and meaningful debt reduction plans.

On balance, the valuation does not look stretched compared with many listed peers, but it also does not look like a deep bargain once you factor in China dependence, high sales returns, underused plants, and the fact that 82.90% of H1 FY26 sales still came from generic products. So this feels more like a fairly priced issue than an obviously cheap one.

Disclaimer: The P/E ratio here is calculated using the company’s post-IPO equity and its most recent FY25 net profits at the upper end of the price band.

Analyst View

GSP Crop Science has a real operating business behind it, not just a market story. It has patents, registrations, five plants, a wide distributor network, improving margins, and a clear plan to use IPO money to reduce debt, which are all positives for medium-term business quality.

But the other side also matters. The company still depends heavily on China for raw materials, has high sales returns, low utilization in some plants, and earns a large share of sales from generic products, which means competition and margin pressure can come back quickly.

So the issue looks more fairly priced than obviously cheap. For investors who understand agrochemicals and are comfortable with medium- to long-term holding, it may be worth tracking closely, but short-term listing excitement looks limited with GMP around zero and with the business facing a few very real operating risks.

For a seamless application process, visit the INDmoney IPO page.

Disclaimer

Source: GSP Crop Science's RHP. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Please be informed that merely opening a trading and demat account will not guarantee investment in securities in the IPO. Investors are requested to do their own independent research and due diligence before investing in an IPO. Please read the SEBI-prescribed Combined Risk Disclosure Document prior to investing. This post is for general information and awareness purposes only and is nowhere to be considered as advice, recommendation, or solicitation of an offer to buy or sell, or subscribe for securities. INDstocks is acting as a distributor for non-broking products/services such as IPO, Mutual Fund, and Mutual Fund SIP. These are not exchange-traded products. All disputes with respect to the distribution activity would not have access to the Exchange investor redressal forum or the Arbitration mechanism. INDstocks Private Limited (formerly known as INDmoney Private Limited) does not provide any portfolio management services, nor is it an investment adviser. Logos above are the property of respective trademark owners, and by displaying them, INDstocks has no right, title, or interest in them. SEBI Stock Broking Registration No: INZ000305337, Trading and Clearing Member of NSE (90267, M70042) and BSE, BSE StarMF (6779), SEBI Depository Participant Reg. No. IN-DP-690-2022, Depository Participant ID: CDSL 12095500, Research Analyst Registration No. INH000018948 BSE RA Enlistment No. 6428.